NCT06306300View on ClinicalTrials.gov

Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)

PHASE4RecruitingINTERVENTIONAL
Enrollment

30,000

Participants

Timeline

Start Date

July 4, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatitis C
Interventions
DRUG

Specialist - Epclusa 400Mg-100Mg Tablet

HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by a specialized doctor.

DRUG

Non- specialist - Epclusa 400Mg-100Mg Tablet

HCV-positive participants from study 1 will be randomized to be treated in the specialist arm, which consists of follow-up by non-specialized doctor.

Trial Locations (2)

21040-360

RECRUITING

Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro

Unknown

RECRUITING

Hugo Perazzo, Rio de Janeiro

All Listed Sponsors
collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

lead

Oswaldo Cruz Foundation

OTHER